Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

HIV-1 Envelope Glycan Composition as a Key Determinant of Efficient Virus Transmission via DC-SIGN and Resistance to Inhibitory Lectins.

Jan M, Upadhyay C, Hioe CE.

iScience. 2019 Nov 22;21:413-427. doi: 10.1016/j.isci.2019.10.030. Epub 2019 Oct 18.

2.

Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.

Hioe CE, Kumar R, Upadhyay C, Jan M, Fox A, Itri V, Peachman KK, Rao M, Liu L, Lo NC, Tuen M, Jiang X, Kong XP, Zolla-Pazner S.

Front Immunol. 2018 Oct 26;9:2441. doi: 10.3389/fimmu.2018.02441. eCollection 2018.

3.

Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins.

Jan M, Upadhyay C, Alcami Pertejo J, Hioe CE, Arora SK.

PLoS One. 2018 Mar 26;13(3):e0194498. doi: 10.1371/journal.pone.0194498. eCollection 2018.

4.

Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations.

Upadhyay C, Feyznezhad R, Yang W, Zhang H, Zolla-Pazner S, Hioe CE.

PLoS Pathog. 2018 Jan 25;14(1):e1006812. doi: 10.1371/journal.ppat.1006812. eCollection 2018 Jan.

5.

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.

Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, Totrov M, Kong XP, Fiore-Gartland AJ, Haigwood NL, Zolla-Pazner S, Hioe CE.

Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0.

6.

Short Communication: Manα1-2Man-Binding Anti-HIV Lectins Enhance the Exposure of V2i and V3 Crown Neutralization Epitopes on the V1/V2 and V3 Hypervariable Loops of HIV-1 Envelope.

Jan M, Upadhyay C, Sharma A, Hioe CE, Arora SK.

AIDS Res Hum Retroviruses. 2017 Sep;33(9):941-945. doi: 10.1089/AID.2016.0262. Epub 2017 Apr 18.

7.

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE.

Vaccine. 2017 Mar 7;35(10):1464-1473. doi: 10.1016/j.vaccine.2016.11.107. Epub 2017 Feb 6.

8.

HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell Activation.

Deng J, Mitsuki YY, Shen G, Ray JC, Cicala C, Arthos J, Dustin ML, Hioe CE.

J Virol. 2016 Nov 14;90(23):10513-10526. doi: 10.1128/JVI.01532-16. Print 2016 Dec 1.

9.

Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Zolla-Pazner S, Powell R, Yahyaei S, Williams C, Jiang X, Li W, Lu S, Wang S, Upadhyay C, Hioe CE, Totrov M, Kong X.

J Virol. 2016 Nov 28;90(24):10993-11006. Print 2016 Dec 15.

10.

Differential effects of HIV transmission from monocyte-derived dendritic cells vs. monocytes to IL-17+CD4+ T cells.

Mitsuki YY, Tuen M, Hioe CE.

J Leukoc Biol. 2017 Jan;101(1):339-350. doi: 10.1189/jlb.4A0516-216R. Epub 2016 Aug 16.

11.

Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.

Shen G, Upadhyay C, Zhang J, Pan R, Zolla-Pazner S, Kong XP, Hioe CE.

PLoS One. 2015 Oct 22;10(10):e0141233. doi: 10.1371/journal.pone.0141233. eCollection 2015.

12.

Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Kumar R, Pan R, Upadhyay C, Mayr L, Cohen S, Wang XH, Balasubramanian P, Nádas A, Seaman MS, Zolla-Pazner S, Gorny MK, Kong XP, Hioe CE.

J Virol. 2015 Sep;89(17):9090-102. doi: 10.1128/JVI.01280-15. Epub 2015 Jun 24.

13.

Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection.

Poles J, Alvarez Y, Hioe CE.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1027-40. doi: 10.1089/aid.2014.0233. Review.

14.

Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages.

Weiden MD, Hoshino S, Levy DN, Li Y, Kumar R, Burke SA, Dawson R, Hioe CE, Borkowsky W, Rom WN, Hoshino Y.

PLoS One. 2014 Oct 1;9(10):e108476. doi: 10.1371/journal.pone.0108476. eCollection 2014.

15.

Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nádas A, Zolla-Pazner S, Hioe CE.

J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.

16.

Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Kumar R, Tuen M, Liu J, Nàdas A, Pan R, Kong X, Hioe CE.

Vaccine. 2013 Nov 4;31(46):5413-21. doi: 10.1016/j.vaccine.2013.09.010. Epub 2013 Sep 16.

17.

Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands.

Alvarez Y, Tuen M, Shen G, Nawaz F, Arthos J, Wolff MJ, Poles MA, Hioe CE.

J Virol. 2013 Oct;87(19):10843-54. doi: 10.1128/JVI.01838-13. Epub 2013 Jul 31.

18.

Imaging of HIV-1 envelope-induced virological synapse and signaling on synthetic lipid bilayers.

Prins KC, Vasiliver-Shamis G, Cammer M, Depoil D, Dustin ML, Hioe CE.

J Vis Exp. 2012 Mar 8;(61). pii: 3757. doi: 10.3791/3757.

19.

Statistical approaches to analyzing HIV-1 neutralizing antibody assay data.

Yu X, Gilbert PB, Hioe CE, Zolla-Pazner S, Self SG.

Stat Biopharm Res. 2012 Jan 1;4(1):1-13.

20.

In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.

Alvarez Y, Tuen M, Nàdas A, Hioe CE.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):823-34. doi: 10.1089/AID.2011.0184. Epub 2011 Dec 1.

21.

HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

van Montfort T, Eggink D, Boot M, Tuen M, Hioe CE, Berkhout B, Sanders RW.

J Immunol. 2011 Nov 1;187(9):4676-85. doi: 10.4049/jimmunol.1101876. Epub 2011 Sep 28.

22.

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Kumar R, Tuen M, Li H, Tse DB, Hioe CE.

Vaccine. 2011 Nov 8;29(48):9064-74. doi: 10.1016/j.vaccine.2011.09.057. Epub 2011 Sep 23.

23.

HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA).

Hioe CE, Tuen M, Vasiliver-Shamis G, Alvarez Y, Prins KC, Banerjee S, Nádas A, Cho MW, Dustin ML, Kachlany SC.

PLoS One. 2011;6(8):e23202. doi: 10.1371/journal.pone.0023202. Epub 2011 Aug 5.

24.

Quantitative assessment of masking of neutralization epitopes in HIV-1.

Agarwal A, Hioe CE, Swetnam J, Zolla-Pazner S, Cardozo T.

Vaccine. 2011 Sep 9;29(39):6736-41. doi: 10.1016/j.vaccine.2010.12.052. Epub 2011 Jan 7.

25.

HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse.

Vasiliver-Shamis G, Dustin ML, Hioe CE.

Viruses. 2010 May 1;2(5):1239-60. doi: 10.3390/v2051239.

26.

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S.

PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.

27.

The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

Hioe CE, Visciano ML, Kumar R, Liu J, Mack EA, Simon RE, Levy DN, Tuen M.

Vaccine. 2009 Dec 11;28(2):352-60. doi: 10.1016/j.vaccine.2009.10.040. Epub 2009 Oct 29.

28.

Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.

Kachlany SC, Schwartz AB, Balashova NV, Hioe CE, Tuen M, Le A, Kaur M, Mei Y, Rao J.

Leuk Res. 2010 Jun;34(6):777-85. doi: 10.1016/j.leukres.2009.08.022. Epub 2009 Sep 10.

29.

Human immunodeficiency virus type 1 envelope gp120-induced partial T-cell receptor signaling creates an F-actin-depleted zone in the virological synapse.

Vasiliver-Shamis G, Cho MW, Hioe CE, Dustin ML.

J Virol. 2009 Nov;83(21):11341-55. doi: 10.1128/JVI.01440-09. Epub 2009 Aug 26.

30.

Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes.

Li H, Xu CF, Blais S, Wan Q, Zhang HT, Landry SJ, Hioe CE.

J Immunol. 2009 May 15;182(10):6369-78. doi: 10.4049/jimmunol.0804287.

31.

The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.

Sachdev DD, Zerhouni-Layachi B, Ortigoza M, Profy AT, Tuen M, Hioe CE, Klotman ME.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):125-9. doi: 10.1097/QAI.0b013e31819f9e31.

32.

Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response.

Visciano ML, Tuen M, Chen PD, Hioe CE.

Infect Agent Cancer. 2008 Jul 18;3:11. doi: 10.1186/1750-9378-3-11.

33.

Human immunodeficiency virus type 1 envelope gp120 induces a stop signal and virological synapse formation in noninfected CD4+ T cells.

Vasiliver-Shamis G, Tuen M, Wu TW, Starr T, Cameron TO, Thomson R, Kaur G, Liu J, Visciano ML, Li H, Kumar R, Ansari R, Han DP, Cho MW, Dustin ML, Hioe CE.

J Virol. 2008 Oct;82(19):9445-57. doi: 10.1128/JVI.00835-08. Epub 2008 Jul 16.

34.

Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.

Li H, Chien PC Jr, Tuen M, Visciano ML, Cohen S, Blais S, Xu CF, Zhang HT, Hioe CE.

J Immunol. 2008 Mar 15;180(6):4011-21.

35.

In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Visciano ML, Tuen M, Gorny MK, Hioe CE.

Virology. 2008 Mar 15;372(2):409-20. Epub 2007 Dec 4.

36.

Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Kaur G, Tuen M, Virland D, Cohen S, Mehra NK, Münz C, Abdelwahab S, Garzino-Demo A, Hioe CE.

Virology. 2007 Dec 5;369(1):214-25. Epub 2007 Sep 4.

37.

The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry.

Williams JG, Tomer KB, Hioe CE, Zolla-Pazner S, Norris PJ.

J Am Soc Mass Spectrom. 2006 Nov;17(11):1560-1569. doi: 10.1016/j.jasms.2006.06.011. Epub 2006 Jul 27.

38.

Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation.

Tuen M, Visciano ML, Chien PC Jr, Cohen S, Chen PD, Robinson J, He Y, Pinter A, Gorny MK, Hioe CE.

Eur J Immunol. 2005 Sep;35(9):2541-51.

39.

Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing.

Chien PC Jr, Cohen S, Tuen M, Arthos J, Chen PD, Patel S, Hioe CE.

J Virol. 2004 Jul;78(14):7645-52.

40.

HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation.

Chien PC Jr, Chen D, Chen PD, Tuen M, Cohen S, Migueles SA, Connors M, Rosenberg E, Malhotra U, Gonzalez C, Hioe CE.

J Infect Dis. 2004 Mar 1;189(5):852-61. Epub 2004 Feb 6.

PMID:
14976603
41.

Propagation of CD4+ T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects.

Cohen S, Tuen M, Hioe CE.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):793-806.

PMID:
14585210
42.

High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression.

Chien PC Jr, Cohen S, Kleeberger C, Giorgi J, Phair J, Zolla-Pazner S, Hioe CE.

J Infect Dis. 2002 Jul 15;186(2):205-13. Epub 2002 Jul 3.

PMID:
12134256
43.

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120.

Hioe CE, Tuen M, Chien PC Jr, Jones G, Ratto-Kim S, Norris PJ, Moretto WJ, Nixon DF, Gorny MK, Zolla-Pazner S.

J Virol. 2001 Nov;75(22):10950-7.

44.

LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission.

Hioe CE, Chien PC Jr, Lu C, Springer TA, Wang XH, Bandres J, Tuen M.

J Virol. 2001 Jan;75(2):1077-82.

45.

Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.

Hioe CE, Jones GJ, Rees AD, Ratto-Kim S, Birx D, Münz C, Gorny MK, Tuen M, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):893-905.

PMID:
10875615
46.
47.

Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization.

Hioe CE, Bastiani L, Hildreth JE, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S247-54. Review.

PMID:
9814951
49.

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, Zolla-Pazner S.

Int Immunol. 1997 Sep;9(9):1281-90.

PMID:
9310831
50.

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides.

Hioe CE, Qiu H, Chend PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O'Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, Nixon DF.

Vaccine. 1996 Apr;14(5):412-8.

PMID:
8735553

Supplemental Content

Support Center